Carter's, Inc. (CRI) is a stock, not an exchange-traded fund, and it draws meaningful coverage from sell-side research. Reviewing individual, attributable targets yields seven current figures: Barclays at $26 (Underweight), Bank of America at $28 (Underperform), Wells Fargo at $30 (Equal-Weight), UBS at $33 (Hold), Goldman Sachs at $38 (Hold), BMO Capital at $40 (Outperform), and Citi at $53 (Buy).
The arithmetic mean of those seven targets is about $35.4, only marginally above the recent share price — so it fails to represent a meaningful upside scenario. Applying the minimum-distance standard, the central target is instead the average of the targets that sit above the current price: Citi's $53, BMO's $40, and Goldman Sachs' $38, which average $43.67, rounded to $44.
The disagreement is instructive. Bulls such as Citi's Paul Lejuez argue the turnaround and margin recovery justify a far higher valuation, while bears such as BofA's Kendall Toscano point to intensifying price sensitivity and a weaker revenue outlook. Recent actions underscore the split: UBS trimmed its target from $38 to $33 in early November 2026, while BMO reaffirmed a $40 target and an Outperform rating in the same window.
With shares recently trading near $34.72, a move to $44 implies upside of roughly 27% — a substantial, though not extreme, move for a mid-cap apparel retailer. The stock's 52-week range of approximately $27 to $44 places the target right at the upper end of where the shares have traded over the past year.
The path depends heavily on whether recent profitability gains can be sustained. Carter's reported second-quarter fiscal 2026 revenue of about $615 million, up roughly 5% year over year and ahead of estimates, with adjusted EPS (earnings per share) of $0.26 versus expectations near $0.06 and an operating margin of about 22.7%. Yet management has guided to full-year net sales growth of only about 2% to 3%, and a third-quarter beat was reportedly overshadowed by a softer revenue outlook.
The $44 area coincides with the stock's 52-week high zone, making it both a natural price objective and a likely resistance level. A durable support level sits near the $27 to $28 zone, near the 52-week low and the more bearish analyst targets. Between these levels, the stock has formed a wide trading range, and any sustained advance toward the upper bound would require a breakout above prior highs rather than a continuation of recent range-bound action.
Analyst price targets typically reflect a roughly 12-month research horizon, though firms do not always state one explicitly and horizons can vary. Investors should watch the next quarterly earnings report and guidance for evidence on whether margin gains and retail momentum are holding, any further analyst target revisions, wholesale order trends, and consumer spending data. Tariff-policy and cost developments also remain relevant to a company still navigating a challenged retail backdrop.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Rather than relying on a single valuation view, the system helps traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently. For those tracking a volatile name like Carter's, such signals can serve as one additional, objective input alongside fundamental research.
Can Carter's stock reach $44? The figure is not a full consensus but the average of the three verified analyst targets above the current price — Citi's $53, BMO's $40, and Goldman Sachs' $38. Reaching it would require a rise of roughly 27% from recent levels near $34.72. The bullish case rests on a dramatic margin recovery, recovered tariff proceeds, and an undemanding valuation, while the bearish case centers on soft guidance, wholesale headwinds, and a handful of targets below the current price. With the full target range spanning $26 to $53, the honest answer is that the outcome depends on whether the turnaround proves durable — a question that upcoming earnings, guidance, and analyst revisions will help resolve.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CRI has been loosely correlated with DBI. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CRI jumps, then DBI could also see price increases.